No Clinically Significant Interaction Between Ezetimibe 10mg and Fenofibrate 145mg
The combination of ezetimibe 10 mg and fenofibrate 145 mg is FDA-approved and safe to use together, with no clinically significant drug interaction that would preclude their concurrent use. 1
FDA-Approved Combination
The FDA explicitly approves ezetimibe in combination with fenofibrate as an adjunct to diet to reduce elevated LDL-C in adults with mixed hyperlipidemia 1. This approval status itself indicates that regulatory review found the combination acceptable from a safety and interaction perspective.
Pharmacokinetic Interaction Profile
While there is a pharmacokinetic interaction, it is not clinically significant:
- Fenofibrate increases ezetimibe exposure (Cmax by ~64% and AUC by ~48%) 2
- However, this increase does not translate to clinical harm because ezetimibe has a flat dose-response curve and an established safety profile across a wide dose range 2
- Ezetimibe does not significantly affect fenofibrate pharmacokinetics 2
Important Safety Monitoring
The FDA label specifies one key precaution when using this combination:
If cholelithiasis (gallstones) is suspected in a patient receiving ezetimibe and fenofibrate, gallbladder studies are indicated, and alternative lipid-lowering therapy should be considered 1. This relates to fenofibrate's known association with increased gallstone risk, not a drug-drug interaction per se.
Clinical Efficacy Data
Multiple studies demonstrate the combination is both safe and effective 2, 3, 4:
- LDL-C reduction: 36-37% with combination vs. 22-23% with either agent alone 3, 4
- Triglyceride reduction: 38-44% 3, 4
- HDL-C increase: 11-19% 3, 4
- Well-tolerated with no significant adverse event imbalances 2, 3, 4
Guideline Support
The 2022 ACC Expert Consensus explicitly lists ezetimibe as FDA-approved "in combination with fenofibrate as an adjunct to diet to reduce elevated LDL-C in adults with mixed hyperlipidemia" 5. The 2014 ACC/AHA guidelines note that fenofibrate may be considered with statins, and by extension, the ezetimibe-fenofibrate combination is recognized for mixed dyslipidemia management 6.
Practical Prescribing Points
- No dose adjustment needed for either medication
- Monitor liver enzymes as clinically indicated (standard for both agents) 1
- Assess for gallbladder symptoms during follow-up
- This combination is particularly useful for patients with mixed dyslipidemia (elevated LDL-C and triglycerides) who cannot tolerate or have contraindications to statins
Bottom line: Use this combination confidently—it's FDA-approved, well-studied, and the pharmacokinetic interaction has no clinical consequences.